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ABSTRACT
Cardiac fibrosis is characterized by accumulation and activation
of fibroblasts and excessive production of extracellular matrix,
which results in myocardial stiffening and eventually leads to
heart failure. Although previous work suggests that protein
kinase C (PKC) isoforms play a role in cardiac fibrosis and
remodeling, the results are conflicting. Moreover, the potential of
targeting PKC with pharmacological tools to inhibit pathologic
fibrosis has not been fully evaluated. Here we investigated the
effects of selected PKC agonists and inhibitors on cardiac
fibroblast (CF) phenotype, proliferation, and gene expression
using primary adult mouse CFs, which spontaneously trans-
differentiate into myofibroblasts in culture. A 48-hour exposure
to the potent PKC activator phorbol 12-myristate 13-acetate
(PMA) at 10 nM concentration reduced the intensity of a-smooth
muscle actin staining by 56% and periostin mRNA levels by
60% compared with control. The decreases were inhibited with
the pan-PKC inhibitor Gö6983 and the inhibitor of classical
PKC isoforms Gö6976, suggesting that classical PKCs regulate
CF transdifferentiation. PMA also induced a 33% decrease in 5-
bromo-2’-deoxyuridine–positive CFs, which was inhibited with
Gö6983 but not with Gö6976, indicating that novel PKC isoforms
(nPKCs) regulate CF proliferation. Moreover, PMA downregu-
lated the expression of collagen-encoding genes Col1a1 and
Col3a1 nPKC-dependently, showing that PKC activation attenu-
ates matrix synthesis in CFs. The partial PKC agonist isophtha-
late derivative bis(1-ethylpentyl) 5-(hydroxymethyl)isophthalate
induced parallel changes in phenotype, cell cycle activity, and
gene expression. In conclusion, our results reveal distinct PKC-
dependent regulation of CF transdifferentiation and proliferation
and suggest that PKC agonists exhibit potential as an antifibrotic
treatment.
SIGNIFICANCE STATEMENT
Cardiac fibrosis is a pathological process that contributes to the
development of heart failure. The molecular mechanisms regu-
lating fibrosis in the heart are, however, not fully understood,
which hinders the development of new therapies. Here, we
demonstrate that classical and novel protein kinase C (PKC)
isoforms distinctly regulate cardiac fibroblast transdifferentiation
and proliferation, the two central processes in fibrosis. Our
results indicate that pharmacological PKC activation may be
a promising strategy to inhibit myocardial fibrosis.
Introduction
Cardiac fibrosis is characterized by transdifferentiation
of fibroblasts into secretory and contractile myofibroblasts
and concomitant accumulation of extracellular matrix in the
myocardium (Kong et al., 2014). Although several cell types
can contribute to fibrotic remodeling indirectly by secreting
profibrotic factors, resident cardiac fibroblasts (CFs) are the
key cell type responsible for fibrosis. Upon pathologic stimuli,
CFs become activated and transdifferentiate into myofibro-
blasts, which exhibit characteristics of both fibroblasts and
smooth muscle cells and produce high amounts of extracellu-
larmatrix proteins (Talman andRuskoaho, 2016). The fibrotic
response is a crucial part of the healing process after
a myocardial infarction (van den Borne et al., 2010; Shinde
and Frangogiannis, 2014). However, prolonged fibroblast
activation in remote areas outside the initial insult area or
due to other stimuli, such as pressure overload, leads to
adverse myocardial remodeling and progressive impairment
of cardiac function. Cardiac fibrosis has been identified as an
independent risk factor in heart failure (Gulati et al., 2013): it
was associated independently, beyond left ventricular ejection
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fraction, with mortality and sudden cardiac death in patients
with dilated cardiomyopathy. Slowing or reversing cardiac
fibrosis is a therapeutic goal in heart failure therapy (Cohn
et al., 2000).
Protein kinase C (PKC) is a group of ten related serine-
threonine protein kinases, which are known to participate in
various signaling pathways and thus regulate, for example,
cell proliferation, differentiation, migration, gene transcrip-
tion and translation, and cell death (Mochly-Rosen et al.,
2012). PKC isoforms can be divided into three subgroups
based on their regulatory region structure and activator
requirements (Steinberg, 2008). The classical isoforms
(cPKCs; a, bI, bII, and g) require both diacylglycerol (DAG)
and calcium for their activation, whereas the novel isoforms
(nPKCs; d, «, h, and u) are activated by DAG alone. A more
distant subgroup of atypical isoforms (z and l/i) does not
respond to either DAG or calcium. The expression of PKC
isoenzymes in myocardium varies between species but also
between normal and diseased state (Palaniyandi et al., 2009).
In the adult human heart, for instance, all isoforms except for
g and u have been detected (Shin et al., 2000; Simonis et al.,
2007). On the other hand, dilated cardiomyopathy leads to
upregulation of PKCb (Bowling et al., 1999), whereas aortic
stenosis leads to upregulation of several isoforms but not
PKCb (Simonis et al., 2007).
The roles of individual PKC isoforms have been investigated
using genetic knockdown and overexpression models, as well
as pharmacological inhibitors. The majority of the reports
suggest that PKC promotes fibrosis. The ATP-competitive
PKCb inhibitor ruboxistaurin reduced cardiac fibrosis and
dysfunction after myocardial infarction in rats (Boyle et al.,
2005) and in mice subjected to pressure overload (Liu et al.,
2009). It also attenuated collagen deposition in a rat diabetic
cardiomyopathy model (Connelly et al., 2009). Moreover,
selective inhibition of PKCbII with a translocation peptide
inhibitor suppressed myocardial fibrosis in hypertensive rats
(Ferreira et al., 2011). Regarding novel PKC isoforms, phar-
macological inhibition of PKC« with a selective translocation
peptide inhibitor reduced fibrosis in hypertensive rats and
collagen secretion from cultured primary CFs stimulated with
transforming growth factor b (TGFb) (Inagaki et al., 2008).
However, there are also contradictory reports suggesting that
PKCmay in fact have a role in limiting cardiac fibrosis. PKC«
knockout mice showed increased fibrosis and elevated expres-
sion of collagen I and III in response to pressure overload
(Klein et al., 2005). Moreover, in vitro selective inhibition of
PKCd with a translocation peptide inhibitor promoted neo-
natal rat CF proliferation (Braun and Mochly-Rosen, 2003).
The aim of this study was to investigate the effect of
pharmacological PKC activation on viability, cell cycle activ-
ity, phenotype, and gene expression of adult mouse primary
CFs in vitro. The compounds include the potent tumor-
promoting PKC activator phorbol 12-myristate 13-acetate
(PMA) and the isophthalate derivative bis(1-ethylpentyl)
5-(hydroxymethyl)isophthalate (HMI-1b11), both of which
activate PKC by binding to the DAG binding sites within
duplicated C1 domains in cPKCs and nPKCs (Boije af Gennäs
et al., 2009, 2011). To clarify the role of different PKC
subfamilies, two PKC inhibitors, Gö6976 and Gö6983, which
differ in their selectivity toward cPKCs and nPKCs, were
used. Our results demonstrate that cPKCs and nPKCs
distinctly regulate proliferation and transdifferentiation of
CFs, the two central cellular processes in the development of
cardiac fibrosis, and indicate that fibroblast-targeted PKC
activation may be a potential therapeutic strategy to inhibit
cardiac fibrosis.
Materials and Methods
Materials. Cell culture media and supplements were purchased
from Gibco (Thermo Fisher Scientific, Paisley, UK). Enzyme P, Red
Blood Cell Lysis Solution (10), gentleMACS C tubes, and gentle-
MACS Dissociator were from Miltenyi Biotec (Bergisch Gladbach,
Germany). DNase I was purchased from AppliChem (Darmstadt,
Germany), Collagenase type 2 from Worthington Biochemical Corpo-
ration (Lakewood, NJ), and gelatin fromMerck Millipore (Darmstadt,
Germany). PMA was purchased from Sigma-Aldrich (Steinheim,
Germany). Diheptan-3-yl 5-(hydroxymethyl)isophthalate (HMI-
1b11) was synthesized at the Division of Pharmaceutical Chemistry
and Technology, Faculty of Pharmacy, University of Helsinki, as
described previously (Boije af Gennäs et al., 2009). PKC inhibitors
Gö6976 and Gö6983 were purchased from Merck Millipore (Billerica,
MA). All reagents used in the cytotoxicity assays were from Sigma-
Aldrich. AlphaLISA SureFire Ultra p-ERK 1/2 (Thr202/Tyr204) and
AlphaLISA SureFire Ultra Total ERK 1/2 assay kits were from
PerkinElmer (Groningen, The Netherlands).
Trans-Blot Turbo Midi PVDF Transfer Packs and 12% Mini-
Protean TGX Stain-Free Protein Gels were purchased from Bio-Rad.
Pierce BCA Protein Assay Kit and SuperSignal West Femto Maxi-
mum Sensitivity Substrate were from Thermo Scientific. The primary
antibodies used inWestern blotting were monoclonal rabbit anti-PKC
alpha (ab32376; Abcam), monoclonal rabbit anti-PKC delta
(ab182126; Abcam), monoclonal rabbit anti-PKC epsilon (ab124806;
Abcam), monoclonal rabbit anti-PKC eta (ab179524; Abcam), and
polyclonal rabbit anti–b-actin (4967; Cell Signaling Technology). The
secondary horseradish peroxidase–linked antibody anti-rabbit lgG
(7074) was from Cell Signaling Technology.
5-Bromo-2’-deoxyuridine (BrdU) was purchased from Abcam (Cam-
bridge, UK). The primary antibodies used in immunofluorescence
stainings were monoclonal mouse anti–a-smooth muscle actin
(a-SMA; A2547; Sigma-Aldrich), polyclonal rabbit anti–discoidin
domain receptor 2 (DDR2) (sc-8989; Santa Cruz Biotechnology),
monoclonal rat anti-BrdU (ab6326; Abcam), and polyclonal rabbit
anti-Ki67 (ab15580; Abcam). The secondary antibodies used were all
purchased from Life Technologies: Alexa Fluor 488 goat anti-mouse
lgG (A11029), Alexa Fluor 546 donkey anti-rabbit lgG (A10040), and
Alexa Fluor 647 goat anti-rat lgG (A21247), with the exception of
Alexa Fluor 594 goat anti-rabbit lgG (ab150080), which was from
Abcam. 4’,6-diamidino-2-phenylindole (DAPI) was from Sigma-
Aldrich.
NucleoSpin RNA kit was from Macherey-Nagel (Düren, Germany).
Transcriptor First Strand cDNA Synthesis kit and LightCycler 480
Probes Master kit were from Roche. TaqMan gene expression assays
for18S (Hs99999901_s1),Actb (Mm00607939_s1),Acta2 (Mm01546133_m1),
Col1a1 (Mm00801666_g1), Col1a2 (Mm00483888_m1), Col3a1
(Mm00802300_m1), Fn1 (Mm01256744_m1), Mmp2 (Mm00439498_m1),
Mmp9 (Mm00442991_m1), Myh10 (Mm00805131_m1), Postn
(Mm01284919_m1), Tgfb1 (Mm01178820_m1), and Tcf21 (Mm00448961_m1)
were purchased from Thermo Fisher Scientific.
Primary Cardiac Fibroblasts. Primary cultures of CFs were
prepared from 10–20-week-old female C57BL/6JOlaHsd mice weigh-
ing 20–22 g (Envigo, Horst, The Netherlands). Animals were eutha-
nized by CO2 narcosis followed by cervical dislocation. Thoracic
cavities were opened, and hearts were perfused through aortas with
2.5 ml of 500 U/ml collagenase II in PBS using a 27 G 12 mm needle.
Ventricles were dissected, cut into small pieces, and transferred into
gentleMACS C tubes (two hearts/tube) containing 5 ml enzyme
solution (Dulbecco’s modified Eagle’s medium containing 400 U/ml
collagenase II, 60 U/ml DNase I, and 10 ml/ml enzyme P). The tissue












pieces were first incubated at 37°C under 300 rpm shaking conditions
for 20 minutes, followed by mechanical digestion with gentleMACS
Dissociator (programm_muscle_01). Enzymatic digestion was contin-
ued with a 30-minute incubation at 37°C under 600 rpm shaking
conditions followed by a second mechanical digestion. The lysate was
quickly centrifuged at 300g, 4°C, and tissue debris was separated from
the cell suspension with a 250 mm tissue strainer. The cell suspension
was centrifuged at 300g, 4°C for 10 minutes. The cell pellet was
resuspended in a buffer solution containing 0.5% bovine serum
albumin and 2 mM EDTA in PBS, pH 7.2. To remove erythrocytes,
red blood cell lysis solution was added according to themanufacturer’s
protocol and incubated for 2 minutes at room temperature (r.t.). After
centrifuging the sample for 10minutes at 300g, 4°C and aspirating the
supernatant, the cells were washed with medium used for fibroblast
culture (Dulbecco’s modified Eagle’s medium/F-12 supplemented with
10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin), and
centrifuged again for 10 minutes at 300g, 4°C. The cells were then
resuspended in culture medium, plated on well plates and let attach
for 2 hours in cell culture conditions (37°C, humidified atmosphere of
5%CO2). To remove dead cells, themediumwas changed before letting
the cells grow overnight prior to compound treatments. For gene
expression and phenotypic studies, cells were grown on gelatin-coated
microscope cover glasses, whereas for viability and cellular kinase
assays and high-content analysis (HCA) they were grown on plastic
96-well plates and for Western blotting on plastic six-well plates.
Cell Viability Assays. The cells were exposed to the compounds
(1–100 nM PMA, 1–30 mM HMI-1b11, 0.1–10 mM Gö6976, 0.1–10 mM
Gö6983) for 24 hours after which necrosis and mitochondrial metab-
olism were investigated using the lactate dehydrogenase (LDH)
and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assays, respectively, as described previously (Talman et al.,
2011). For the LDH assay, 50 ml of culture medium was transferred
from each well onto a new 96-well plate followed by addition of 50 ml
substrate solution containing 1.3 mM b-nicotinamide adenine di-
nucleotide, 660 mM iodonitrotetrazolium, 54 mM L(+)-lactic acid,
280 mM phenazine methosulfate, and 0.2 M Tris-HCl (pH 8.0). After
a 30-minute incubation at r.t. the reactionwas stopped by adding 50ml
of 1 M acetic acid to each well, and absorbance was measured at
490 nm using Victor2 plate reader (PerkinElmer, Turku, Finland).
Spontaneous LDH release was measured from untreated cells,
maximal LDH release from cells lysed with 0.9% Triton X-100, and
background absorbance from wells without cells (medium only). After
subtracting background, cytotoxicity was calculated as follows: cyto-
toxicity percentage = [(sample – spontaneous LDH release)/(maximal
LDH release – spontaneous LDH release)]  100. For the MTT assay,
MTT was added to the cells at a final concentration of 0.5 mg/ml
followed by a 2-hour incubation in cell culture conditions. Themedium
was aspirated and formazan crystals were solubilized in DMSO.
Absorbance was measured at 550 nm, and absorbance at 650 nm
was subtracted as background.
Cellular Kinase Assay. The cells were exposed to the compounds
(10 nM PMA or 10 mM HMI-1b11 with or without 1 mM Gö6976 or
1 mM Gö6983) for 30 minutes after which they were lysed and the
amount of phosphorylated extracellular signal-regulated kinases
1/2 (p-ERK1/2) and total extracellular signal-regulated kinases 1/2
(ERK1/2) were detected using AlphaLISA SureFire Ultra p-ERK 1/2
(Thr202/Tyr204) and AlphaLISA SureFire Ultra Total ERK 1/2 assay
kits according to the manufacturer’s protocol. The cells were lysed in
80 ml lysis buffer, and 30 ml of the lysate was transferred from each
well to two 96-well 1/2 AreaPlates (PerkinElmer) for assays. The
lysates were then incubated with the Acceptor bead mix for 1 hour at
r.t., followed by addition of the Donor bead mix and a further 5-hour
incubation at r.t. The Alpha signal was measured using EnSpire
Alpha plate reader (PerkinElmer, Turku, Finland) with standard
AlphaLISA settings.
Western Blotting. The cells were exposed to the compounds
(10 nM PMA or 10 mM HMI-1b11 with or without 1 mM Gö6983) for
48 hours after which they were lysed with 1% SDS in 50 mM Tris-HCl
(pH 7.5), and genomic DNA was sheared with a 25 G needle. Protein
concentrations were determined with bicinchoninic acid protein assay
kit. From each sample 10 mg of total protein was resolved on
a 12% Mini-protean TGX stain-free gel and transferred by Trans-
Blot Turbo transfer system to polyvinylidene difluoride membranes.
After blocking the nonspecific background with 5% nonfat milk in
Tris-buffered saline with 0.05% Tween 20 (TTBS) for 1 hour at r.t.,
the membranes were incubated with primary antibodies (anti-PKCa
1:1000, anti-PKCd 1:5000, anti-PKC« 1:1000, anti-PKCh 1:2000,
anti–b-actin 1:1000 dilution in 5%milk-TTBS) overnight at 4°C. After
washing with TTBS, the membranes were incubated for 1 hour at r.t.
with horseradish peroxidase–conjugated secondary antibody (1:2000
dilution in 5% milk-TTBS). Bands were detected with an enhanced
chemiluminescent substrate using ChemiDoc XRS+ (Bio-Rad) or
Luminescent Imager Analyzer LAS-3000 (Fujifilm) and relative
densities were quantified using Fiji ImageJ 1.52 software. Optical
densities of PKC isoform immunoreactive bands were adjusted to
corresponding b-actin bands from the same membranes.
Nonautomated Fluorescence Microscopy and Phenotypic
Analysis. The cells were grown in mere cell culture medium for
1–3 days after cell isolation or they were exposed to PKC agonists
(10 nM PMA or 10 mM HMI-1b11) and inhibitors (1 mM Gö6976 or
1 mM Gö6983) 24 hours after isolation for 48 hours. The cells were
fixed with 4% paraformaldehyde for 15 minutes at r.t. and permea-
bilized with 0.1% Triton X-100 for 10 minutes. The cells were then
washed 2  10 minutes with Dulbecco’s PBS containing 0.2% bovine
serum albumin (DB) and incubated at r.t. for 60minutes with primary
antibodies: anti–a-SMA (1:200) and anti-DDR2 (1:50) diluted in DB.
After three 5-minute washes with DB, the cells were incubated with
Alexa Fluor–conjugated secondary antibodies (1:200) andDAPI (1mg/ml)
at r.t. for 45 minutes. After three 5-minute washes, the microscope
cover glasses were mounted onmicroscope slides with Prolong Gold
Antifade Mountant and imaged with Leica DM6000B fluorescence
wide field microscope (Leica Microsystems, Wetzlar, Saksa) and
CMOS camera (Hamamatsu Orca-Flash4.0 V2, Hamamatsu Photonics,
Hamamatsu, Japan). The objective was 20/0.7 HC PL APO CS, and
the software was Leica Application Suite X (Leica Microsystems,
Wetzlar, Germany). The imageswere analyzed using CellProfiler image
analysis software. For quantification, the cells were first identified
based on DAPI fluorescence, which defined the nuclear area, and the
cell area was defined by extending the nuclear area with the area
defined byDDR2 staining. Integrated intensity of a-SMA stainingwas
then quantified from each individual cell.
Automated Fluorescence Microscopy and High Content
Analysis. For HCA of CF proliferation, the cells were stained,
imaged, and analyzed as described previously (Karhu et al., 2018).
The cells were exposed to the compounds (10 nM PMA or 10 mMHMI-
1b11 with or without 1 mMGö6976 or 1 mMGö6983) for 48 hours, and
10 mM BrdU was added to the culture medium for the last 24 hours
before fixation. The cells were fixed with 4% paraformaldehyde for
15 minutes at r.t. and permeabilized with 0.1% Triton X-100 for
10 minutes. DNA was hydrolyzed with 2 M HCl for 30 minutes (r.t.)
followed by neutralization with 0.1 M sodium borate (pH 8.5) for
30 minutes. Nonspecific binding sites were blocked with 4% FBS in
PBS for 45 minutes (r.t.). The cells were incubated 60 minutes with
primary antibodies: anti–a-SMA (1:200), anti-BrdU (1:250), and anti-
Ki67 (1:250) diluted in 4% FBS. After 3  5-minute washes with PBS,
the cells were incubated with Alexa Fluor–conjugated secondary
antibodies (1:200) and DAPI (1 mg/ml) at r.t. for 45 minutes. The
96-well plates were imaged and analyzed with CellInsight CX5 High-
Content Screening Platform (Thermo Scientific) using a 10 objective
(Olympus UPlanFL N 10/0.3). For quantification of BrdU-positive
and Ki67-positive CFs, the cells were first identified based on DAPI
fluorescence, which defined the nuclear area. The thresholds for
BrdU+ and Ki67+ cells were set manually in each experiment to
adjust for slight variation in staining intensities.
Quantitative Real-Time Polymerase Chain Reaction. The
cells were exposed to the compounds (10 nMPMA or 10 mMHMI-1b11












with or without 1 mM Gö6976 or 1 mM Gö6983) for 48 hours, after
which they were lysed, and RNA was isolated using NucleoSpin
RNA kit (Macherey-Nagel, Düren, Germany) according to the
manufacturer’s protocol. Samples were lysed in 350 ml lysis buffer
containing 1% b-mercaptoethanol. Total RNA was transcribed
into cDNA with Transcriptor First Strand cDNA Synthesis kit
(Roche, Mannheim, Germany) following the manufacturer’s pro-
tocol using random hexamer primers. Quantitative polymerase
chain reaction (qPCR) was performed using TaqMan assays
(Thermo Fisher Scientific), LightCycler 480 Probes Master kit
(Roche), and LightCycler 480 Real-Time PCR machine (Roche).
The results were analyzed using the DDCt method and adjusted to
the average of two housekeeping genes (18S and Actb) from the
same samples.
Ethics. The animals were housed and terminated in accordance
with the 3R principles of the European Union directive 2010/63/EU
governing the care and use of experimental animals, and following
local laws and regulations [Finnish Act on the Protection of Animals
Used for Scientific or Educational Purposes (497/2013), Government
Decree on the Protection of Animals Used for Scientific or Educational
Purposes (564/2013)]. The use of animals for collecting tissues was
reviewed and approved by Laboratory Animal Center, Helsinki
Institute of Life Sciences, University of Helsinki (internal license
KEK17-012).
Statistics. For statistical analysis, non-normalized raw data were
used, with the exceptions of kinase assay for which total ERK1/2-
normalized values were used, qPCR for which DCt values were used,
and Western blotting for which b-actin–adjusted values were used.
Statistical analyses were performed using IBM SPSS Statistics 25
software. Statistical significance was evaluated with randomized
block ANOVA (experiment and treatment as factors) followed by
Dunnett’s post hoc test. Differences at the level of P , 0.05 were
considered statistically significant.
Results
The Effect of PKC Agonists and Inhibitors on
Cardiac Fibroblast Viability. We first examined the effect
of PKC agonists and inhibitors on the viability of CFs.
Based on the MTT assay, 24-hour exposure to PMA at the
concentrations of 10 nM and 100 nM caused small
23% [95% confidence interval (CI) 11–34; P = 0.004] and
14% (95% CI 0–30; P = 0.062) decreases, respectively, in
viability of CFs (Supplemental Fig. 1). Exposure to partial
PKC agonist HMI-1b11 at the concentration of 30 mM de-
creased metabolic activity 70% (95% CI 54–85; P , 0.001) but
at 10 mM concentration HMI-1b11 slightly increased it
(28%; 95% CI 5–52; P = 0.025), compared with control. A
treatment with the pan-PKC inhibitor Gö6983 had no effect
on CF viability, whereas the inhibitor of classical PKCs
(Gö6976) decreased cell viability concentration-depen-
dently: 17% (95% CI 12–22) at 1 mM concentration and
39% (95% CI 30–48; P = 0.004) at 10 mM concentration.
Based on the LDH assay results, only HMI-1b11 at the
highest 30 mM concentration exhibited a noticeable cyto-
toxic response; after a 24-hour exposure the LDH release
was 35% of the maximal (95% CI 27–45; P , 0.001;
Supplemental Fig. 1). PMA and the PKC inhibitors induced
less than 10% increase in cytotoxicity even with the highest
concentrations. Concentrations for the proliferation and
transdifferentiation experiments were selected based on
the present results regarding toxicity and previous reports
regarding in vitro efficacy of the compounds (Talman et al.,
2013; Sarajärvi et al., 2018). Furthermore, as PMA induces
downregulation of several PKC isoforms at 100 nM
(Johnson et al., 1995), the 10 nM concentration was chosen
to avoid downregulation.
The Effect of PKC Agonists and Inhibitors on ERK1/2
Phosphorylation in Cardiac Fibroblasts. To confirm the
effect of PMA and HMI-1b11 on PKC, activation of mitogen
activated protein kinase kinase–extracellular signal-regulated
kinase pathway, a known downstream signaling pathway of
PKC (Schönwasser et al., 1998; Mackay and Twelves, 2007),
was studied by measuring ERK1/2 phosphorylation in CFs
using AlphaLISA assay. A 30-minute exposure to PMA at
10 nM concentration and HMI-1b11 at 10 mM concentration
induced 2.9-fold (95% CI 1.9–4.0; P = 0.016) and 2.6-fold
(95% CI 1.8–3.5; P = 0.037) increases, respectively, in the
amount of p-ERK1/2 compared with DMSO-control (Fig. 1A).
Moreover, the increases in p-ERK1/2 were inhibited with the
pan-PKC inhibitor Gö6983 but not with the cPKC inhibitor
Gö6976, suggesting that PKC agonist-mediated ERK1/2 acti-
vation is mediated by nPKCs in CFs.
The Effect of PKC Agonists and Inhibitors on PKC
Protein Levels in Cardiac Fibroblasts. We then analyzed
PKC protein levels to verify the expression of selected
isoenzymes in mouse CFs and to assess whether PMA or
HMI-1b11 cause PKC downregulation in our experimental
design. Based on our previous RNA sequencing data (Talman
et al., 2018), the main PKC isoforms expressed in mouse heart
are a, d, «, h, and l (the mouse homolog of human PKCi; Webb
et al., 2000) (Supplemental Fig. 2). As the C1 domain of
atypical PKCl does not bind C1 domain ligands analogous to
DAG, including PMA andHMI-1b11 (Steinberg, 2008; Talman
et al., 2014b), only the classical (a) and novel (d, «, and h)
isoforms of these five isoforms abundant in mouse hearts were
selected for Western blot analysis. Firstly, all four isoforms
were detected in total cell homogenates, and thus their
expression in mouse cardiac (myo)fibroblasts was verified
(Figs. 1, B–F). Secondly, neither PMA at 10 nM concentration
nor HMI-1b11 at 10 mM concentration had effect on PKCa,
PKC«, or PKCh protein levels after 48-hour exposure.
However, both PKC activators induced a minor downregu-
lation of PKCd, which was not inhibited by coexposure to the
pan-PKC inhibitor Gö6983. The PMA-induced decrease was
25% (95% CI 13–37; P = 0.040) and HMI-1b11–induced
decrease 34% (95% CI 20–48; P = 0.003) compared with
control.
The Effect of PKC Agonists and Inhibitors on
Cardiac Fibroblast Phenotype. To characterize the pri-
mary cell culture and to study the phenotype of CFs, we used
DDR2 as a marker of fibroblasts and a-SMA as a marker of
myofibroblasts. DDR2 was chosen because within the heart
it is only expressed in fibroblasts (Goldsmith et al., 2004).
a-SMA, on the other hand, is expressed in smooth muscle cells
but also serves as a marker of activated and transdifferenti-
ated fibroblasts, myofibroblasts, which have a key role in scar
formation and myocardial remodeling after cardiac injury
(van den Borne et al., 2010). Based on DDR2 expression,
approximately 98% of the cells in the primary cultures were
CFs (Supplemental Fig. 4). Moreover, when cultured in mere
cell culture medium, CFs acquired a myofibroblast phenotype
within 72 hours from plating as demonstrated by a-SMA
expression. The relative a-SMA staining intensity increased
5.8-fold (95% CI 1.9–9.7; P = 0.030) between 24- and 72-hour
time points (Supplemental Fig. 4). This spontaneous phenotypic












change (previously reported in Wang et al., 2003) was then
further used to investigate the effects of PKC agonists on CF
transdifferentiation. Both PKC agonists, PMA at 10 nM and
HMI-1b11 at 10 mM concentration, inhibited fibroblast
transdifferentiation to myofibroblasts after 48-hour expo-
sure (Fig. 2, A and B). PMA induced a 56% reduction (95% CI
47–65;P = 0.011) in the integrated intensity ofa-SMA staining
compared with DMSO-control (Fig. 2C). This decrease
appeared to be cPKC dependent as it was prevented with
both the cPKC inhibitor Gö6976 and the pan-PKC inhibitor
Gö6983. AlsoHMI-1b11 decreased the expression of a-SMA by
34% (95% CI 33–35; P = 0.018), and the inhibitors partially
attenuated the effect. The inhibitors alone had no effect on
a-SMA expression (Fig. 2C).
The Effect of PKC Agonists and Inhibitors on
Cardiac Fibroblast Proliferation. To investigate the ef-
fect of PKC activation on cell cycle activity of CFs, HCA of
BrdU and Ki67 stainings was used. After a 48-hour exposure,
PMA induced a 33% decrease (95% CI 24–42; P = 0.018) in
BrdU-positive and a 36% decrease (95% CI 8–64; P = 0.008) in
Ki67-positive CFs compared with DMSO-control (Fig. 3).
These decreases were nPKC dependent as they were inhibited
with the pan-PKC inhibitor Gö6983 but not with the cPKC
inhibitor Gö6976. PKC inhibitors alone had no effect on cell
cycle activity of CF when compared with DMSO. The par-
tial PKC agonist HMI-1b11 had no effect on BrdU-positive
cells but induced a 15% (95% CI 0–30) decrease in Ki67-
positive cells.
The Effect of PKC Agonists and Inhibitors on Gene
Expression in Cardiac Fibroblasts. To study the effects of
PKC activation on the expression of genes related to cardiac
fibrosis, we analyzed mRNA levels with qPCR after treating
CFs with the PKC agonists and/or inhibitors for 48 hours.
Both PKC agonists decreased the expression of several genes
that encode structural proteins of cardiac extracellular ma-
trix (Fig. 4). PMA decreased the expression of type I and III
Fig. 1. The effect of PKC agonists and inhibitors
on ERK1/2 phosphorylation and PKC protein
levels in primary cardiac fibroblasts isolated
from adult mice. (A) For cellular kinase assay,
the cells were exposed to PKC agonists (10 nM
PMA or 10 mM HMI-1b11) with or without PKC
inhibitors (1 mMGö6976, 1 mMGö6983) 24 hours
after plating for 30 minutes. The amount of total
ERK1/2 and p-ERK1/2 was quantified from cel-
lular lysates using Alpha technology. The results
are shown as ratios of p-ERK1/2 to total ERK1/2.
(B–F) For Western blotting, the cells were ex-
posed to PKC agonists (10 nM PMA or 10 mM
HMI-1b11) with or without PKC inhibitor (1 mM
Gö6983) 24 hours after plating for 48 hours and
lysed, and total proteins were extracted. (B)
Representative Western blots of PKC isoforms
and respective b-actin blots as loading controls.
The full blots are shown in Supplemental Fig. 3.
(C–F) Relative densities of PKC isoform immu-
noreactive bands adjusted to the corresponding
b-actin bands. (C) PKCa. (D) PKCd. (E) PKC«. (F)
PKCh. Results are displayed as scatter plots
showing data values from independent experi-
ments (n = 3), with means indicated by a line and
error bars representing S.D.. The data are nor-
malized to DMSO-control. *P ˂ 0.05 vs. DMSO-
control (randomized block ANOVA followed by
Dunnett’s post hoc test); **P ˂ 0.01 vs. DMSO-
control.












collagen-encoding genes Col1a1 (47%; 95% CI 34–60; P =
0.003; Fig. 4A) and Col3a1 (64%; 95% CI 59–69; P , 0.001;
Fig. 4C) and tended to decrease Col1a2 (26%; 95% CI 15–37;
Fig. 4B) as well as glycoprotein fibronectin–encodingFn1 gene
(30%; 95%CI 17–43; Fig. 4D). CompoundHMI-1b11 decreased
the expression ofCol3a1 (53%; 95%CI 43–63; P = 0.007; Fig. 4C)
and slightly Fn1 (22%; 95% CI 15–29; Fig. 4D) compared with
DMSO-control. All of these decreases were nPKC dependent as
they were inhibited or attenuated with the pan-PKC inhibitor
Gö6983 but not with the cPKC inhibitor Gö6976. In fact,
coexposure to Gö6976 tended to further decrease the mRNA
levels of these structural protein–encoding genes, in particular
with the weaker PKC activator HMI-1b11.
The expression of Postn gene that encodes for the matricel-
lular protein periostin decreased after a 48-hour exposure to
PKC agonists (Fig. 4E): 60% in PMA-treated cells (95% CI
39–81; P = 0.005) and 48% in HMI-1b11–treated cells (95% CI
28–68; P = 0.022). The effect was inhibited with both
inhibitors, suggesting it was cPKC dependent. At the same
time, themRNA level ofActa2 that encodes contractile protein
a-SMA was not affected by exposure to PMA but was
36% lower (95% CI 34–38; P = 0.004) in HMI-1b11–treated
cells when compared with control (Fig. 4F). The cPKC in-
hibitor Gö6976 increased the transcription of Acta2 with or
without coexposure to PKC agonists, whereas the pan-PKC
inhibitor Gö6983 had no effect on Acta2 expression. Expres-
sion of TGFb1-encoding gene Tgfb1 was upregulated by HMI-
1b11 (54%; 95% CI 34–74; P = 0.019), whereas coexposure
to the inhibitors, especially Gö6983, attenuated the effect
(Fig. 4G). Gö6976 alone increased the expression of Tcf21
(transcription factor 21 encoding) gene (P = 0.011; Fig. 4H)
compared with DMSO. Similarly, coexposure to PMA and
Gö6983 increased Tcf21 mRNA levels when compared with
DMSO (P = 0.023). Gö6976, with or without coexposure to the
PKC agonists, tended to slightly increase the expression of
Myh10 (myosin heavy chain 10 encoding gene) aswell (Fig. 4I).
Moreover, PKC agonists and inhibitors had distinct effects on
the expression of Mmp2 (Fig. 4J) and Mmp9 (Fig. 4K) that
encode matrix metalloproteinases. PMA or HMI-1b11 alone
had no effect on the expression ofMmp2, whereas coexposure to
the cPKC inhibitor Gö6976 increased the expression when
compared with DMSO-control: PMA + Gö6976, 52% (95% CI
2–102; P = 0.037), and HMI-1b11 + Gö6976, 80% (95% CI
27–133; P = 0.014). On the other hand, the expression ofMmp9
increased 2.6-fold (95% CI 1.6–3.7; P = 0.035) compared with
control after a 48-hour exposure to PMA. In HMI-1b11–treated
cells the increasewasmoremodest (1.3-fold; 95%CI 0.7–1.8). In
both cases the effect was attenuated with coexposure to Gö6976
and Gö6983, suggesting it was cPKC dependent.
Discussion
Although numerous studies have been published regarding
the role of PKC in heart failure, the results are conflicting and
Fig. 2. The effect of PKC agonists and inhibitors on a-SMA expression in
primary cardiac fibroblasts isolated from adult mice. The cells were
exposed to PKC agonists (10 nM PMA or 10 mM HMI-1b11) with or
without PKC inhibitors (1 mM Gö6976, 1 mM Gö6983) 24 hours after
plating for 48 hours. At 72 hours after plating, the cells were fixed and
stained. (A and B) Representative images of a-SMA staining. Original
magnification, 20. (C) Quantified intensity of a-SMA staining. Results are
displayed as scatter plots showing data values from independent experi-
ments (n = 3), with means indicated by a line and error bars representing
S.D. The data are normalized to DMSO-control. *P ˂ 0.05 vs. DMSO-control
(randomized block ANOVA followed by Dunnett’s post hoc test)












sometimes difficult to interpret. Moreover, the roles of in-
dividual PKC isoforms in CF proliferation and transdiffer-
entiation, two central processes in the development of fibrosis,
and the potential of targeting PKC with pharmacological
compounds to inhibit pathologic fibrosis have not been fully
elucidated. Therefore, in this study our aim was to character-
ize CF proliferation, phenotype, and gene expression in
response to selected proprietary and commercially available
PKC agonists and inhibitors.
Overall, previous reports suggest that PKC isoforms play
a role in cardiac fibrosis and remodeling. Their partially
overlapping and redundant roles as well as compensatory
changes in the expression of other PKC isoforms in knockdown
models, however, complicate the interpretation of the results
and may explain the sometimes conflicting outcomes (Klein
et al., 2005; Gallegos and Newton, 2008; Song et al., 2015).
Furthermore, the effect of PKC activation or inhibition is often
cell type and stimulus dependent. In addition, the context-
dependent regulation of PKC activity is not thoroughly un-
derstood. Using pharmacological tools for modulating PKC is
not straightforward either as even compounds that were
originally reported to be isoform selective have proven to
exert cellular actions also via other PKC isoforms and kinases
(Steinberg and Sussman, 2005;Wu-Zhang andNewton, 2013).
Additionally, not much is known about the role of PKC
specifically in CFs. Most reports concerning the effects of
PKC in cardiac fibrosis are from in vivo studies, which makes
it difficult to decipher whether the effects on fibroblasts are
direct or indirect. Better understanding of the role of PKC in
CF activation would help the identification of the PKC
isoforms that could serve as therapeutic targets for the
treatment of adverse myocardial remodeling.
All PKC agonists and modulators used in this study proved
to be relatively nontoxic to mouse CFs. Only compounds HMI-
1b11 and Gö6976 with the highest concentrations tested (30
mM and 10 mM, respectively) showed substantial toxicity.
Based on the HCA, PMA-induced activation of nPKCs de-
creased CF proliferation. Parallel decrease in the viability of
PMA-treated cells, as measured by the MTT assay, may also
be explained with decreased cell division and thus lower cell
density compared with control. Based on current knowledge,
the activation and proliferation of resident fibroblasts repre-
sent the most important source of myofibroblasts in the
fibrotic heart (Tallquist and Molkentin, 2017). Thus, inhibit-
ing both CF transdifferentiation and proliferation might have
potential as a therapeutic strategy for pathologic fibrosis. In
Fig. 3 The effect of PKC agonists and inhibitors on cell cycle activity of primary cardiac fibroblasts isolated from adult mice. The cells were exposed to
PKC agonists (10 nM PMA or 10 mM HMI-1b11) with or without PKC inhibitors (1 mM Gö6976, 1 mM Gö6983) 24 hours after plating for 48 hours. At
72 hours after plating, the cells were fixed and stained. Representative images of BrdU (A) and Ki67 (B) staining. Original magnification, 10.
Quantifications for the proportion of BrdU-positive cells (C) andKi67-positive cells (D). Results are expressed asmeans + S.D. (n = 3). *P ˂ 0.05 vs. DMSO-
control (randomized block ANOVA followed by Dunnett’s post hoc test); **P ˂ 0.01 vs. DMSO-control.












our study, both PKC agonists decreased a-SMA expression,
a hallmark of CF transdifferentiation, although PMA was
more effective compared with partial agonist HMI-1b11. In
addition to a-SMA, periostin has been described as an un-
derlying marker of cardiac myofibroblasts (Kanisicak et al.,
2016). In our study, the changes observed in the expression of
Postn in response to PKC activators and inhibitors were
comparable to the changes noted in a-SMA protein levels.
Taken together, our results suggest that cPKCs are responsi-
ble for the PKC activator–induced inhibition of CF trans-
differentiation. Moreover, the expression of collagen-encoding
genes showed comparable nPKC-dependent regulation in
Fig. 4. The effect of PKC agonists and inhibitors on gene expression in primary cardiac fibroblasts isolated from adult mice. The cells were exposed to
PKC agonists (10 nM PMA or 10 mM HMI-1b11) with or without PKC inhibitors (1 mM Gö6976, 1 mM Gö6983) 24 hours after plating for 48 hours. At
72 hours after plating, mRNA was extracted and measured by qPCR. The levels of transcripts were adjusted to the average of two housekeeping genes
(18S and Actb) from the same samples. (A) Col1a1. (B) Col1a2. (C) Col3a1. (D) Fn1. (E) Postn. (F) Acta2. (G) Tgfb1. (H) Tcf21. (I) Myh10. (J) Mmp2. (K)
Mmp9. Results are displayed as scatter plots showing data values from independent experiments (n = 3), with means indicated by a line and error bars
representing S.D. The data are normalized to DMSO-control. *P ˂ 0.05 vs. DMSO-control (randomized block ANOVA followed by Dunnett’s post hoc test);
**P ˂ 0.01 vs. DMSO-control; ***P ˂ 0.001 vs. DMSO-control.












response to PKC agonists and inhibitors as cell proliferation,
indicating that PKC agonists may attenuate the production of
new matrix proteins.
Interestingly, the changes seen in Acta2 mRNA levels were
not parallel to those in a-SMA protein levels. This poor
correlation between gene and protein expression could be
due to timing: both analyses were done after 48-hour com-
pound exposures (72 hours after cell isolation). Additionally, it
is possible that PKC activation does not actually regulate
a-SMA expression on mRNA level but on later stages of the
protein synthesis or degradation processes. Another interest-
ing finding was the Gö6976-induced increase in Acta2 mRNA
levels, with or without coexposure to PKC agonists. Consid-
ering Gö6976 has been shown to be a highly promiscuous
inhibitor of other kinases besides classic PKC isoenzymes
(Davies et al., 2000; Anastassiadis et al., 2011), it can be
speculated that this effect on Acta2 expression is likely PKC
independent.
Although several different markers used in the present
study were regulated by PKC agonists and inhibitors, not all
genes generally associated with fibrosis were affected, or the
effect was ambiguous. This in part demonstrates the complex
nature of fibrosis and the numerous factors that take part in
regulating fibrotic responses. Eventually, what takes place on
tissue level depends not only on the sum of all different factors
but also on cooperation between different cell types. This can,
for example, explain the unexpected increase in Tgfb1 expres-
sion in CFs in response to PKC agonists. Although TGFb
induces myofibroblast transdifferentiation and enhances col-
lagen production (Petrov et al., 2002), it is produced by several
cell types in vivo and has multiple functions and roles in
cardiac tissue during injury and remodeling (Dobaczewski
et al., 2011).
Based on our previous RNA sequencing data (Talman et al.,
2018), the main cPKCs and nPKCs expressed in adult mouse
heart are a, d, «, and h, which coincides with the analysis from
Schreiber et al. (2001). Our present results indicate that the
main cPKC isoform in mouse CFs is PKCa, moreover suggest-
ing that PKCa regulates myofibroblast transdifferentiation.
This is in line with the study by Gao et al. (2003), which
showed that inhibition of PKC with calphostin C or deletion of
PKCa with antisense PKCa oligodeoxynucleotides inhibited
TGFb-induced a-SMA expression in rat aortic adventitial
fibroblasts. Furthermore, we show that the main nPKCs
expressed in the mouse heart are also expressed in CFs,
thus suggesting that proliferation and collagen production in
CFs are regulated via PKCd, PKC«, and/or PKCh. On the
other hand, long-term PKC activation by PMA causes down-
regulation of PKC protein levels through proteasome-
dependent and -independent degradation (Young et al.,
1987). Interestingly, 48-hour exposures to PMA (at 10 nM)
or HMI-1b11 (at 10 mM) tended to downregulate PKCd, but
not other isoenzymes. This minor downregulation was
comparable to that reported in SH-SY5Y neuroblastoma
cells after a 24-hour exposure to 10 mM HMI-1b11, but not
as noticeable as in SH-SY5Y cells or cardiomyocytes treated
with 100 nM PMA (Johnson et al., 1995; Sarajärvi et al.,
2018). This together with our data demonstrating nPKC-
mediated ERK1/2 activation in response to PMA or HMI-
1b11 further support the conclusion that the observed
effects are due to PKC activation and not inhibition by
downregulation.
It is noteworthy that the cells used were isolated from
healthy adult female mice. PKC isoform expressions and
thereby PKC-mediated signaling may change in diseased
state, likely resulting in changes in the effects of PKC-
targeted compounds. Furthermore, it is possible that the age
and the sex of the animals used could explain some of the
discrepancies of the present results with previous studies.
However, as most of the previous work has been conducted
in vivo and using rats, we consider that the drastic difference
of in vivo and in vitro conditions as well as the species
differences are more plausible causes for the discrepancies
observed. Another limitation of the present study are the
pharmacological tools targeting multiple PKC isoenzymes but
also other kinases. However, parallel usage of Gö6976 and
Gö6983 provides a valuable tool to analyzewhether an effect is
a result of nPKC activity or cPKC activity or is PKC in-
dependent. Furthermore, using the inhibitors in combination
with C1 domain-targeting PKC activators, which only bind to
two other serine-threonine kinases, protein kinase D and
dystrophy kinase-related Cdc42 binding kinase (Colón-
González and Kazanietz, 2006; Talman et al., 2014a), fur-
ther strengthens the conclusion of PKC-mediated effects.
Isoenzyme-specific silencing could be used to investigate the
role of individual PKC isoforms in CFs. Redundant roles of
closely related PKC isoforms and compensatory expression
changes in other isoforms may, however, limit the conclusions
from such experiments. Furthermore, PKC also has non-
catalytic functions (Ling et al., 2007; Cameron et al., 2008;
Zeidman et al., 1999), mainly via protein-protein interactions,
and thus genetic silencing and pharmacological tools target-
ing certain PKC isoforms may not always produce similar
functional outcomes.
In conclusion, by characterizing mouse CFs in response to
several different PKC agonists and inhibitors, we revealed
that PKC agonists (1) inhibit CF transdifferentiation into
myofibroblasts, (2) decrease CF proliferation, and (3) decrease
expression of collagen-encoding genes in CFs. Moreover, we
discovered that CF transdifferentiation is regulated via
cPKCs, whereas CF proliferation and collagen gene expres-
sion are regulated via nPKCs. Overall, our results suggest
that activation of PKC in CFs may be a promising strategy to
inhibit pathologic cardiac remodeling. As downregulation of
PKC in response to irreversible PKC activation by ultrapotent
PKC agonists such as PMA is considered to cause tumor
promotion previously attributed to PKC activation (Antal
et al., 2015; Newton and Brognard, 2017), weaker or partial
agonists that do not downregulate PKC completely, such as
the isophthalate HMI-1b11, represent promising leads for
PKC-targeted antifibrotic therapies. Further studies in mul-
ticellular environment and pathophysiological context are,
however, required to establish proof of concept.
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